• Search
  • Advanced Search

Original Article

July 31, 2026


Frequent Genetic Alterations in Metastatic Prostate Cancer Revealed by Targeted Sequencing
Seung-Hwan Jeong, Jang Hee Han, Hyeong Dong Yuk, et al.
J Urol Oncol. 2026;24(2):101-108.

Purpose: This study used the Seoul National University Hospital FIRST-Cancer Panel (v3.2.2) to identify potentially druggable targets in prostate cancer. We compared genetic alterations between primary, treatmentnaive, hormone-sensitive prostate cancer...

Original Article

July 31, 2026


GATA6 Alteration as a Potential Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated With Docetaxel After Androgen Receptor Pathway Inhibitor Failure
Ja Yoon Heo, Chung Lee, Heesun Shin, et al.
J Urol Oncol. 2026;24(2):109-118.

Purpose: This study aimed to evaluate the prognostic significance of GATA6 alterations in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel after androgen receptor pathway inhibitor (ARPI) failure. Materials and...

Original Article

July 31, 2026


Expression of Phosphatase-Tensin Homolog and Erythroblast Transformation-Specific Related Genes in Prostate Carcinoma Cases Seen at Osun State University Teaching Hospital, Osogbo, Osun State, Nigeria: A 5-Year Retrospective Observational Study
Olujuwon Towoju, Ganiat Omoniyi-Esan, Akinwumi Komolafe, et al.
J Urol Oncol. 2026;24(2):119-126.

Background: Prostate carcinoma is the second most common cancer in men worldwide and a leading cause of cancer-related mortality, particularly in low- and middle-income countries. Prognostic assessment relies largely on...

Original Article

July 31, 2026


Lesion Volume Dynamics Add Prognostic Value Beyond Prostate Imaging Reporting and Data System Score Increase for Predicting Confirmatory Biopsy Upgrade During Active Surveillance
Theodoros Karanikolas, Jonah Tripp, Morgan Joseph, et al.
J Urol Oncol. 2026;24(2):127-136.

Purpose: This study aimed to evaluate the association of Prostate Imaging Reporting and Data System (PIRADS) score increase and lesion volume progression on serial prostate magnetic resonance imaging (MRI) with...

Brief Report

July 31, 2026


Long-term Follow-up After Prostate-Specific Antigen Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Eric A. Miller, Paul F. Pinsky
J Urol Oncol. 2026;24(2):137-141.

Current prostate cancer (PCa) screening guidelines for prostate-specific antigen (PSA) testing recommend informed discussions between patient and provider for men aged 55–69 years due to inconsistent trial results and benefit...

Brief Report

July 31, 2026


Prostate-Specific Antigen Surveillance Rates in Sexual Minority Prostate Cancer Survivors During the COVID-19 Pandemic
Ryan Haggart, Alex J. Bates, Badrinath R. Konety, et al.
J Urol Oncol. 2026;24(2):142-146.

While the coronavirus disease 2019 pandemic necessitated delays in nonurgent healthcare, the specific impact on sexual minority cancer patients has remained largely unexamined. In this cross-sectional observational subanalysis of the...

Original Article

July 31, 2026


Integrated Immunophenotypic Stratification of Urothelial Carcinoma Using CK14, FOXA1, and p16: Correlation With Clinicopathological Features and Patient Outcomes
Mona Saeed Mohammed, Nashaat Mohammed Salama
J Urol Oncol. 2026;24(2):147-157.

Purpose: Molecular classification of urothelial carcinoma (UC) has important prognostic and therapeutic implications, but routine genomic profiling is not feasible in many settings. Immunohistochemistry (IHC) offers a practical alternative. This...

Brief Report

July 31, 2026


Specificity of a Urine-Based PENK Methylation Test (EarlyTect Bladder Cancer) in Patients With Benign Urologic Conditions and Healthy Controls
Sang Hun Song, Sangchul Lee
J Urol Oncol. 2026;24(2):158-161.

Bladder cancer (BC) diagnosis relies primarily on cystoscopy and urine cytology. Although cystoscopy is the gold standard, it is invasive and costly, and urine cytology, although noninvasive, has limited sensitivity....

Original Article

July 31, 2026


Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma
Theodore Joseph Miller, Junjia Zhu, Megan Wheelden, et al.
J Urol Oncol. 2026;24(2):162-171.

Purpose: Tyrosine kinase inhibitors (TKIs) used to treat advanced renal cell carcinoma are associated with clinically significant toxicities, including hypertension and acute kidney injury. Because angiotensin-converting enzyme inhibitors and angiotensin...

Review Article

July 31, 2026


Updates on Renal Mass Ablation
Simon Roh, Peter Lee
J Urol Oncol. 2026;24(2):172-181.

Incidental renal masses detected on imaging performed for nonrenal indications are increasingly common in contemporary practice. Appropriate management is essential to achieve favorable patient outcomes while avoiding unnecessary intervention. Percutaneous...

Letter to the Editor

July 31, 2026


A Commentary on “Radical Nephrectomy and Thrombectomy Without Cardiopulmonary Bypass for Level IV Venous Thrombus Renal Cell Carcinoma: Feasibility and Technical Tips”
Matthew Gaynor, Gaetano Ciancio
J Urol Oncol. 2026;24(2):182-183.
Current Issue
Volume 24(2); Jul 2026
Nephron-Sparing Surgery for Upper Urinary Tract Urothelial Carcinoma  (11,240 times)
Sung Han Kim, Ilma S. Savul, Seth P. Lerner
J Urol Oncol. 2024;22(1):68-77.

Invited Review

Mar 31, 2024

Bladder Cancer
Pathologic Diagnosis of Renal Cell Carcinoma in the Era of the 2022 World Health Organization Classification: Key Points for Clinicians  (11,010 times)
Bokyung Ahn, Jinahn Jeong, Yong Il Lee, et al.
J Urol Oncol. 2024;22(2):115-127.

Invited Review

Jul 31, 2024

Renal Cell Carcinoma
Poorer Outcomes in Bladder Cancer Patients With Diabetes: A Systematic Review and Meta-analysis Addressing Over 226,472 Bladder Cancer Patients  (8,436 times)
Stefani Frost, Parisa Ziarati, Ryan Moen, et al.
J Urol Oncol. 2024;22(1):78-94.

Systemic Review and Meta-analysis

Mar 31, 2024

Bladder Cancer
The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer  (7,634 times)
Jong Ho Park, Jong Jin Oh
J Urol Oncol. 2024;22(3):246-255.

Invited Review

Nov 30, 2024

Bladder Cancer
Prognostic Impact of Seminal Vesicle Mucosal Invasion in pT3b Prostate Cancer Following Radical Prostatectomy  (7,210 times)
Hyun Jung Lee, Won Hoon Song, Seung Soo Lee, et al.
J Urol Oncol. 2025;23(1):30-37.

Original Article

Mar 31, 2025

Prostate Cancer
Robot-Assisted Radical Nephrectomy With Inferior Vena Cava Thrombectomy: A Narrative Review With Step-by-Step Procedures  (7,123 times)
Seokhwan Bang, Sung-Hoo Hong
J Urol Oncol. 2024;22(2):105-114.

Invited Review

Jul 31, 2024

Renal Cell Carcinoma
Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study  (6,990 times)
Joohyun Hong, Ghee Young Kwon, Minyong Kang, et al.
J Urol Oncol. 2024;22(1):59-67.

Original Article

Mar 31, 2024

Kidney Cancer
Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review  (6,952 times)
Chang Wook Jeong
J Urol Oncol. 2024;22(1):4-10.

Invited Review

Mar 31, 2024

Prostate Cancer
Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review  (6,807 times)
Minseok Suh, Gi Jeong Cheon
J Urol Oncol. 2024;22(1):11-20.

Invited Review

Mar 31, 2024

Prostate Cancer
Determinant of Aggressive Phenotype in Metastatic Hormone-Sensitive Prostate Cancer Depends on an Intrinsic, Highly Aggressive Cell Cluster: Integrated Single-Cell RNA and Whole Transcriptomic Sequencing Analyses  (6,708 times)
Minyong Kang, ByulA Jee, Jiwoong Yu, et al.
J Urol Oncol. 2025;23(2):98-111.

Original Article

Jul 31, 2025

Prostate Cancer
Factors Associated With Pericardial Effusion and Mortality in Renal Cancer Patients  (6,641 times)
Kennedy E. Okhawere, Jewel Bamby, Indu Saini, et al.
J Urol Oncol. 2025;23(2):148-163.

Original Article

Jul 31, 2025

Kidney Cancer
High-Grade Late Urinary Toxicity Following Salvage Radiotherapy After Radical Prostatectomy: A Retrospective Cohort Study  (6,366 times)
Seung-Kwon Choi, Myong Kim, Sang Mi Lee, et al.
J Urol Oncol. 2024;22(1):21-28.

Original Article

Mar 31, 2024

Prostate Cancer
Exploring the Evolving Role of Metastasectomy in Advanced Renal Cell Carcinoma  (6,235 times)
Jongkyou Kwon, Sungun Bang, Kang Su Cho
J Urol Oncol. 2024;22(3):228-236.

Invited Review

Nov 30, 2024

Kidney Cancer
Artificial Intelligence: The Latest Advances in the Diagnosis of Bladder Cancer  (5,886 times)
Satyendra Singh, Ram Mohan Shukla
J Urol Oncol. 2024;22(3):268-280.

Review Article

Nov 30, 2024

Bladder Cancer
Health Equity Research Outcomes and Improvement Consortium Prostate Cancer Health Precision Africa1K: Closing the Health Equity Gap Through Rural Community Inclusion  (5,771 times)
Vanessa M. Hayes, Sean M. Patrick, Joyce Shirinde, et al.
J Urol Oncol. 2024;22(2):144-149.

Invited Review

Jul 31, 2024

Prostate Cancer
The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer  (5,715 times)
Ho Kyung Seo, Eui Hyun Jung, Sora Yang, et al.
J Urol Oncol. 2024;22(2):166-177.

Invited Review

Jul 31, 2024

Bladder Cancer
Trimodal Therapy in the Treatment of Muscle-Invasive Bladder Cancer  (5,609 times)
Yongsoo Jo, Hyeong Dong Yuk
J Urol Oncol. 2024;22(3):256-267.

Invited Review

Nov 30, 2024

Bladder Cancer
Global Renal Cell Carcinoma Research Trends Over 30 Years: A PRISMA-Compliant Bibliometric Analysis  (5,383 times)
Jung Hoon Kim, Ji Woong Hwang
J Urol Oncol. 2024;22(1):42-51.

Original Article

Mar 31, 2024

Kidney Cancer
Smart Nanocarriers as an Emerging Platform in Urologic Cancer Immunotherapy: A Review on Clinical Insights and Applications  (5,196 times)
Sania Hassan, Afshan Ayaz, Afaf Nawaz, et al.
J Urol Oncol. 2025;23(2):164-187.

Review Article

Jul 31, 2025
Comparison of Outcomes Between Radical Nephrectomy and Partial Nephrectomy in Clinical T2 Renal Cell Carcinoma: A Retrospective Korean Renal Cell Carcinoma Cohort Study  (5,156 times)
Younsoo Chung, Seok-Soo Byun, Sung Kyu Hong, et al.
J Urol Oncol. 2024;22(2):136-143.

Original Article

Jul 31, 2024

Renal Cell Carcinoma
Early Experience of the Single-Port Robotic Transvesical Radical Prostatectomy: Case Series  (4,900 times)
Jae Hoon Chung, Hwanik Kim, Woo Jin Bang, et al.
J Urol Oncol. 2024;22(3):188-195.

Original Article

Nov 30, 2024

Prostate Cancer
Adverse Prognosis in Dialysis Patients Undergoing Systemic Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Study  (4,808 times)
Shun Iwasa, Ryuichi Mizuno, Keishiro Fukumoto, et al.
J Urol Oncol. 2025;23(2):140-147.

Original Article

Jul 31, 2025

Kidney Cancer
A Narrative Review on Systemic Therapy for Renal Cell Carcinoma in the Perioperative Setting  (4,769 times)
Isamu Tachibana, Qian Qin, Jacob Taylor, et al.
J Urol Oncol. 2024;22(2):100-104.

Invited Review

Jul 31, 2024

Renal Cell Carcinoma
Prognostic Factors and Cancer-Specific Survival of Surgically Managed Renal Cell Carcinoma With Venous Thrombus: A 30-Year Experience at a Tertiary Referral Center  (4,531 times)
Hyun Young Lee, Yunjoong Kim, Bumjin Lim, et al.
J Urol Oncol. 2024;22(1):52-58.

Original Article

Mar 31, 2024

Kidney Cancer
Decisional Trade-offs in Localized Prostate Cancer: A Prospective Cross-Sectional Study of Radical Prostatectomy, Radiation Therapy, and Active Surveillance  (4,521 times)
Hyunho Han, Youngdeuk Choi, Woong Kyu Han, et al.
J Urol Oncol. 2025;23(2):112-118.

Original Article

Jul 31, 2025

Prostate Cancer
Targeted Therapy Following Metastasectomy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis  (4,479 times)
Hui Mo Gu, Seung Il Jung, Dongdeuk Kwon, et al.
J Urol Oncol. 2024;22(1):34-41.

Systemic Review and Meta-analysis

Mar 31, 2024

Kidney Cancer
JUO, the Journal of Urologic Oncology, Celebrates Its Second Anniversary  (4,436 times)
Cheol Kwak
J Urol Oncol. 2024;22(1):1-3.

Editorial

Mar 31, 2024
Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study  (4,425 times)
Sung Hee Lim, Sung Wook Cho, Jae Hoon Chung, et al.
J Urol Oncol. 2024;22(1):29-33.

Original Article

Mar 31, 2024

Prostate Cancer
Expression and Prognostic Value of VEGF, VEGFR1, VEGFR2, VEGFR3, and E-Cadherin in Clear Cell Renal Cell Carcinoma  (4,418 times)
Mónica Sanz del Pozo, Joaquín Gimeno Pelegrín, Nebay Rodríguez Muñoz, et al.
J Urol Oncol. 2025;23(2):132-139.

Original Article

Jul 31, 2025

Kidney Cancer
The Current Role of Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma  (4,406 times)
Hyung Joon Kim
J Urol Oncol. 2024;22(3):224-227.

Brief Report

Nov 30, 2024

Kidney Cancer

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org
Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: leeseh@yuhs.ac

Copyright © The Korean Urological Oncology Society.

Developed in M2PI